The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of cetuximab, pemetrexed, cisplatin and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small cell lung cancer (NSCLC): Results of the IFCT-0803 trial.
Jean Tredaniel
No relevant relationships to disclose
Fabrice Barlesi
No relevant relationships to disclose
Cecile Le Pechoux
No relevant relationships to disclose
Delphine Lerouge
No relevant relationships to disclose
Eric Pichon
No relevant relationships to disclose
Sylvestre Le Moulec
No relevant relationships to disclose
Lionel Moreau
No relevant relationships to disclose
Sylvie Friard
No relevant relationships to disclose
Virginie Westeel
No relevant relationships to disclose
Lidia Petit
No relevant relationships to disclose
Olivier Carre
No relevant relationships to disclose
Francois Guichard
No relevant relationships to disclose
Olivier Raffy
No relevant relationships to disclose
Julie Villa
No relevant relationships to disclose
Alain Prevost
No relevant relationships to disclose
Marie Paule Lebitasy
No relevant relationships to disclose
Franck Morin
No relevant relationships to disclose
Gerard Zalcman
No relevant relationships to disclose
Francoise Mornex
No relevant relationships to disclose